Quintet Private Bank Europe S.A. Boosts Stake in Eli Lilly and Company $LLY

Quintet Private Bank Europe S.A. increased its holdings in Eli Lilly and Company (NYSE:LLY) by 55.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,028 shares of the company’s stock after purchasing an additional 15,762 shares during the period. Eli Lilly and Company accounts for 2.4% of Quintet Private Bank Europe S.A.’s holdings, making the stock its 10th biggest holding. Quintet Private Bank Europe S.A.’s holdings in Eli Lilly and Company were worth $50,944,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in LLY. Osbon Capital Management LLC bought a new stake in Eli Lilly and Company in the 4th quarter worth approximately $25,000. Basso Capital Management L.P. bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth about $30,000. Maseco LLP boosted its position in shares of Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after buying an additional 28 shares during the period. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new position in Eli Lilly and Company in the 4th quarter valued at $39,000. Finally, Aventus Investment Advisors Inc. increased its stake in Eli Lilly and Company by 270.0% in the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock worth $34,000 after buying an additional 27 shares during the period. Institutional investors own 82.53% of the company’s stock.

Insider Activity

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock worth $15,958,170 in the last quarter. Corporate insiders own 0.14% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analyst raises price target: Cantor Fitzgerald lifted its LLY price target to $1,440 from $1,410 and maintained an “overweight” rating, signaling confidence in Lilly’s long-term earnings outlook. Benzinga coverage
• Positive Sentiment: Technical momentum improves: LLY recently moved above its 50-day moving average, a technical signal that may attract short-term buyers and suggests improving near-term momentum. Eli Lilly overtakes 50-day moving average
• Positive Sentiment: Pipeline supports the long-term case: Investors continue to highlight strong GLP-1 demand, oncology growth and next-generation obesity candidate retatrutide. Retatrutide’s potential efficacy and a possible FDA filing in 2027 could provide another major growth catalyst. Three bargains outside AI
• Neutral Sentiment: Oncology remains a developing growth driver: Jaypirca, Inluriyo and Retevmo could help offset slower Verzenio sales and declines from mature products, although the financial impact will depend on commercial execution and upcoming results. Eli Lilly oncology portfolio ahead of earnings
• Negative Sentiment: Valuation and competition remain overhangs: Analysts note that LLY trades at a demanding multiple, while increasing competition in the GLP-1 market and potential pricing pressure could limit the pace of future earnings growth. New WHO childhood-obesity guidance may also create uncertainty around the market’s long-term expansion. Is the LLY dip a buying opportunity?

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded down $34.00 on Thursday, hitting $1,154.72. The company’s stock had a trading volume of 1,479,126 shares, compared to its average volume of 2,966,079. The company has a market capitalization of $1.09 trillion, a price-to-earnings ratio of 38.71, a price-to-earnings-growth ratio of 1.42 and a beta of 0.46. Eli Lilly and Company has a 1 year low of $783.85 and a 1 year high of $1,292.65. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The firm has a fifty day moving average price of $1,173.51 and a 200-day moving average price of $1,094.59.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter in the prior year, the business posted $6.31 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 36.66 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on LLY. Citigroup upped their target price on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 23rd. UBS Group set a $1,376.00 price target on shares of Eli Lilly and Company in a research note on Friday, August 7th. Wells Fargo & Company lifted their target price on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Finally, TD Cowen reaffirmed a “buy” rating and issued a $1,250.00 price target on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,313.43.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.